How a Fortune 50 workforce lowered health care costs by nearly 30% with Daylight®

The new health economic research report by a Johns Hopkins professor shows how the use of a digital therapeutic can lower overall healthcare costs.

Poor mental health is a common and expensive challenge for employers. Mental health difficulties continue to be a substantial issue, with one in five US adults experiencing mental illness in 2020 (NAMI, 2022) and two in five US adults reporting symptoms of anxiety and depression (Kuehn, 2022). Not only are these mental health difficulties common, but they are also costly.

In this white paper we evaluate the impact of Daylight, a digital therapeutic solution for anxiety, among an employee population and discuss the impacts it had on the employer’s health care costs.

Key insights:

  • Identifying the common and core symptoms of anxiety disorders
  • Understanding how anxiety is linked with increased employee health care costs
  • Reviewing how digital therapeutics (DTx) work and are scaled throughout populations
  • Learning the relationship between DTx efficacy and health care cost savings
  • Determining the implications for businesses like yours

A peek inside:

Disclaimer: Daylight is available as an adjunct to usual medical care for generalized anxiety disorder for adults ages 18 and older, without FDA review under their COVID-19 policy.

Copy Link

Download the report

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023